Amalgamated Bank Tyme Technologies, Inc. Transaction History

Amalgamated Bank

$12.1 Billion
Q3 2024

Shares

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2021 Aug 16, 2021	SELL	$1.14 - $1.87 $11,926 - $19,563	-10,462 Closed	0 $0
Q3 2020 Oct 30, 2020	SELL	$0.93 - $1.35 $25 - $36	-27 Reduced 0.26%	10,462 $10,000
Q2 2020 Aug 10, 2020	SELL	$0.97 - $1.7 $108 - $190	-112 Reduced 1.06%	10,489 $14,000
Q1 2020 May 13, 2020	SELL	$0.9 - $1.95 $324 - $702	-360 Reduced 3.28%	10,601 $12,000
Q3 2019 Nov 13, 2019	SELL	$0.97 - $1.77 $26 - $47	-27 Reduced 0.25%	10,961 $13,000
Q2 2019 Aug 14, 2019	SELL	$0.96 - $1.89 $2,098 - $4,131	-2,186 Reduced 16.59%	10,988 $13,000
Q1 2019 May 15, 2019	BUY	$1.76 - $3.73 $989 - $2,096	562 Added 4.46%	13,174 $23,000
Q4 2018 Feb 15, 2019	BUY	$2.01 - $4.21 $25,350 - $53,096	12,612 New	12,612 $47,000

About TYME TECHNOLOGIES, INC.

Ticker TYME
Exchange NASDAQ
Shares Outstandng 172,207,008
Description
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...

More about TYME

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.